# Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

> **NCT00863798** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 682 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Desvenlafaxine Succinate Sustained-Release 10mg
- **DRUG:** Desvenlafaxine Succinate Sustained-Release 50 mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00863798
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 682 (ACTUAL)
- **Last updated:** 2011-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00863798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00863798, "Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00863798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*